Rivaroxaban in Patients With Recent Peripheral Artery Impairment: The VOYAGER PAD Trial

Journal of the American College of Cardiology

78, 757-759

DOI: 10.1016/j.jacc.2021.06.021

Citation Report

#	Article	IF	Citations
1	Sex Differences in Peripheral Artery Disease. Circulation Research, 2022, 130, 496-511.	15.7	190
2	Current Status and Principles for the Treatment and Prevention of Diabetic Foot Ulcers in the Cardiovascular Patient Population: A Scientific Statement From the American Heart Association. Circulation, 2024, 149, e232-e253.	24.6	125
3	Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interventional Cardiology Clinics, 2024, 13, 553-559.	1.1	1
4	Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. Journal of the American College of Cardiology, 2024, 84, 936-952.	12.0	24
5	Ten Tips to Manage Oral Anticoagulation in Hemodialysis Patients With Atrial Fibrillation. CKJ: Clinical Kidney Journal, 2024, 17, sfae270.	4.8	12
6	Society for Vascular Surgery Clinical Practice Guideline on the Management of Intermittent Claudication: Focused Update. Journal of Vascular Surgery, 2025, 82, 303-326.e11.	3.4	28
7	Peripheral Artery Disease. Nature Reviews Disease Primers, 2025, 11, 68.	81.2	41
8	Antiplatelet Therapy for Peripheral Arterial Disease. , 2025, .		0
9	Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial. American Journal of Nephrology, 2026, .	3.9	1
10	Eligibility for Dual Pathway Inhibition in Patients With Peripheral Artery Disease Undergoing Revascularization. Journal of Cardiovascular Medicine, 2026, 27, 306-317.	2.3	2
11	Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 2026, 336, 296-305.	37.0	8